Why is there a growing reliance among precision oncology specialists on full exome sequencing with NGS -- such as that provided by FoundationOne Medicine -- as opposed to targeted, hotspot panels?

Why is there a growing reliance among precision oncology specialists on full exome sequencing with NGS -- such as that provided by FoundationOne Medicine -- as opposed to targeted, hotspot panels?

Why is there a growing reliance among precision oncology specialists on full exome sequencing with NGS — such as that provided by FoundationOne Medicine — as opposed to targeted, hotspot panels? What critical information does the report provide?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Janice Tsang, MBBS, MRCP(UK), FRCP (Lond.)

Janice Tsang, MBBS, MRCP(UK), FRCP (Lond.)

Specialist in Medical Oncology
Hon. Clinical Assistant Professor
Li Ka Sing Faculty of Medicine
The University of Hong Kong